Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Adaptive Biotechnologies Corp (ADPT) vs Oxford Lane Capital Corp (OXLC) Price & Performance

Adaptive Biotechnologies CorpTrade
Oxford Lane Capital CorpTrade

Price performance (Past 24H)

Key statistics

Adaptive Biotechnologies Corp vs Oxford Lane Capital Corp — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while Oxford Lane Capital Corp trades at $9.52 (market cap $909.61M). The key difference: Adaptive Biotechnologies Corp is far larger — about 4.4× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays a 25.76% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.

ADPTOXLC
Market Cap
$4.04B$909.61M
Sector
HealthFinancials
52-Week High
$25.45$18.75
52-Week Low
$12.30$8.15
Enterprise Value
$4.10B
Dividend Yield
25.76%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Adaptive Biotechnologies Corp

Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.

The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.

Oxford Lane Capital Corp

OXLC trades at $9.51, up 2.59% today, with a bullish technical signal from moving averages but a neutral RSI. The stock shows mixed fundamentals: a low P/B of 0.88 suggests undervaluation, but negative ROE and ROA highlight profitability challenges. Recent earnings misses and a sharp revenue decline in 2026 contrast with consistent $0.20 monthly dividends. News sentiment is divided, with some highlighting high yield opportunities and others warning of NAV erosion and unsustainable payouts.

The outlook is cautious due to earnings volatility and high yield sustainability concerns. Opportunities include deep discount to book value and analyst buy ratings, but risks involve persistent net income losses, negative cash flow from operations, and potential dividend cuts if NAV declines continue.

Returns comparison

Trailing returns across standard periods

About Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.

Read more on ADPT

About Oxford Lane Capital Corp

Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.

Read more on OXLC